CPA
ARCT icon

Capital Performance Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Capital Performance Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$46 – 338
2024
Q3 		$46 Buy
+2
New +$43 ﹤0.01% 2797

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Performance Advisors's ARCT Position: Q4 2024 in Review

Capital Performance Advisors sold out of Arcturus Therapeutics (ARCT) in Q4 2024, closing a stake of 2 shares — an estimated $46 sold.

Capital Performance Advisors first reported a position in ARCT in Q3 2024 and held it in 1 quarter. The position peaked at $46 in Q3 2024. 147 funds tracked by Wall St. Rank hold ARCT as of Q4 2024.

  • Capital Performance Advisors reported no remaining Arcturus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 2 Arcturus Therapeutics shares in Q4 2024, an estimated $46.
  • Capital Performance Advisors first reported a position in Arcturus Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Arcturus Therapeutics position peaked at $46 in Q3 2024.
  • 147 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.